Create a PowerPoint presentation on lysosomal engineering offer 10 slideshow which is included introduction of about a lysosomes and structure of lysosome, lysosome used in biotechnology, drug delivery with example, glutac mechanism and enzyme replacement therapy its limitations ,application s of lysosomal engineering , resent research paper included conclusion, reference, thank you
lysosomal engineering drug delivery enzyme replacement therapy
lysosomal engineering GLUTAC mechanism recent research 2024 2025
PMID: 40149863
PMID: 40208336
mkdir -p /tmp/workspace/lysosomal-engineering && ls /tmp/workspace/lysosomal-engineering/
~/lysosomal-engineering/build_pptx.py
from pptx import Presentation
from pptx.util import Inches, Pt, Emu
from pptx.dml.color import RGBColor
from pptx.enum.text import PP_ALIGN, MSO_ANCHOR
from pptx.oxml.ns import qn
from io import BytesIO
# ── Colour palette ──────────────────────────────────────────────────────────
DARK_BLUE = RGBColor(0x0D, 0x2B, 0x6B) # slide header bar
MID_BLUE = RGBColor(0x1A, 0x73, 0xE8) # accent / title text
TEAL = RGBColor(0x00, 0x96, 0x88) # bullet icon bar
LIGHT_GREY = RGBColor(0xF4, 0xF6, 0xF9) # slide background
WHITE = RGBColor(0xFF, 0xFF, 0xFF)
DARK_GREY = RGBColor(0x33, 0x33, 0x33)
GOLD = RGBColor(0xF9, 0xA8, 0x25)
W = Inches(13.333)
H = Inches(7.5)
def new_prs():
prs = Presentation()
prs.slide_width = W
prs.slide_height = H
return prs
def blank(prs):
return prs.slides.add_slide(prs.slide_layouts[6])
def fill_bg(slide, color):
from pptx.util import Pt
background = slide.background
fill = background.fill
fill.solid()
fill.fore_color.rgb = color
def add_rect(slide, x, y, w, h, color):
shape = slide.shapes.add_shape(
1, # MSO_SHAPE_TYPE.RECTANGLE
x, y, w, h
)
shape.fill.solid()
shape.fill.fore_color.rgb = color
shape.line.fill.background()
return shape
def add_tb(slide, x, y, w, h, text, size, bold=False, color=DARK_GREY,
align=PP_ALIGN.LEFT, wrap=True, italic=False):
tb = slide.shapes.add_textbox(x, y, w, h)
tf = tb.text_frame
tf.word_wrap = wrap
tf.margin_left = 0; tf.margin_right = 0
tf.margin_top = 0; tf.margin_bottom = 0
p = tf.paragraphs[0]
p.alignment = align
run = p.add_run()
run.text = text
run.font.size = Pt(size)
run.font.bold = bold
run.font.italic = italic
run.font.color.rgb = color
run.font.name = "Calibri"
return tb
def add_para(tf, text, size, bold=False, color=DARK_GREY,
align=PP_ALIGN.LEFT, bullet_char=None, space_before=6):
p = tf.add_paragraph()
p.alignment = align
p.space_before = Pt(space_before)
if bullet_char:
run0 = p.add_run()
run0.text = bullet_char + " "
run0.font.size = Pt(size)
run0.font.color.rgb = TEAL
run0.font.name = "Calibri"
run = p.add_run()
run.text = text
run.font.size = Pt(size)
run.font.bold = bold
run.font.color.rgb = color
run.font.name = "Calibri"
return p
def header_bar(slide, title_text, subtitle_text=""):
"""Dark top bar with title + optional subtitle."""
add_rect(slide, 0, 0, W, Inches(1.35), DARK_BLUE)
add_tb(slide, Inches(0.4), Inches(0.15), Inches(12.5), Inches(0.7),
title_text, 30, bold=True, color=WHITE, align=PP_ALIGN.LEFT)
if subtitle_text:
add_tb(slide, Inches(0.4), Inches(0.85), Inches(12.5), Inches(0.45),
subtitle_text, 15, bold=False, color=GOLD, align=PP_ALIGN.LEFT)
def bottom_bar(slide, text="Lysosomal Engineering | 2025"):
add_rect(slide, 0, Inches(7.15), W, Inches(0.35), DARK_BLUE)
add_tb(slide, Inches(0.3), Inches(7.16), Inches(12.5), Inches(0.32),
text, 9, color=WHITE, align=PP_ALIGN.RIGHT)
# ════════════════════════════════════════════════════════════════════════════
# SLIDE 1 – Title Slide
# ════════════════════════════════════════════════════════════════════════════
def slide1_title(prs):
sl = blank(prs)
fill_bg(sl, DARK_BLUE)
# Decorative teal stripe
add_rect(sl, 0, Inches(3.5), Inches(0.18), Inches(2.5), TEAL)
add_rect(sl, 0, Inches(0), W, Inches(0.08), GOLD)
add_tb(sl, Inches(0.45), Inches(1.2), Inches(12.4), Inches(1.2),
"LYSOSOMAL ENGINEERING", 48, bold=True, color=WHITE, align=PP_ALIGN.CENTER)
add_tb(sl, Inches(0.45), Inches(2.55), Inches(12.4), Inches(0.7),
"Structure • Function • Drug Delivery • Therapeutic Applications",
20, bold=False, color=GOLD, align=PP_ALIGN.CENTER, italic=True)
add_rect(sl, Inches(2.5), Inches(3.55), Inches(8.3), Inches(0.04), TEAL)
add_tb(sl, Inches(0.45), Inches(3.85), Inches(12.4), Inches(0.5),
"A Comprehensive Overview", 16, color=RGBColor(0xBB, 0xD6, 0xFF),
align=PP_ALIGN.CENTER)
# Organelle icon as text art
add_tb(sl, Inches(0.45), Inches(4.4), Inches(12.4), Inches(1.6),
"Biotechnology | Drug Delivery | Gene Therapy | Enzyme Replacement",
13, color=RGBColor(0x90, 0xCA, 0xF9), align=PP_ALIGN.CENTER)
add_tb(sl, Inches(0.45), Inches(6.4), Inches(12.4), Inches(0.6),
"Prepared using peer-reviewed sources • 2025", 10,
color=RGBColor(0x88, 0xAA, 0xCC), align=PP_ALIGN.CENTER, italic=True)
# ════════════════════════════════════════════════════════════════════════════
# SLIDE 2 – Introduction to Lysosomes
# ════════════════════════════════════════════════════════════════════════════
def slide2_intro(prs):
sl = blank(prs)
fill_bg(sl, LIGHT_GREY)
header_bar(sl, "Introduction to Lysosomes",
"The Cell's Recycling and Degradation Hub")
bottom_bar(sl)
tb = sl.shapes.add_textbox(Inches(0.4), Inches(1.5), Inches(7.8), Inches(5.4))
tf = tb.text_frame; tf.word_wrap = True
tf.margin_left = 0; tf.margin_top = 0
p = tf.paragraphs[0]; p.alignment = PP_ALIGN.LEFT
r = p.add_run(); r.text = "What are Lysosomes?"
r.font.size = Pt(18); r.font.bold = True
r.font.color.rgb = MID_BLUE; r.font.name = "Calibri"
bullets = [
("Discovered by Christian de Duve in 1955 (Nobel Prize 1974)", False),
("Membrane-bound organelles found in all eukaryotic cells", False),
("Diameter: 0.1 – 1.2 µm; acidic interior (pH 4.5 – 5.0)", False),
("Contain >60 hydrolytic enzymes (cathepsins, lipases, nucleases)", False),
("Central hub for: autophagy, phagocytosis, endocytosis & exocytosis", False),
("Dysfunction → Lysosomal Storage Disorders (LSDs): Gaucher, Fabry, Pompe", False),
("Emerging role in cancer, neurodegeneration & metabolic diseases", False),
]
for txt, bold in bullets:
add_para(tf, txt, 13.5, bold=bold, bullet_char="▸", space_before=5)
# Right info-box
add_rect(sl, Inches(8.5), Inches(1.5), Inches(4.5), Inches(5.4), DARK_BLUE)
tb2 = sl.shapes.add_textbox(Inches(8.65), Inches(1.6), Inches(4.2), Inches(5.2))
tf2 = tb2.text_frame; tf2.word_wrap = True
tf2.margin_left = 0; tf2.margin_top = 0
p2 = tf2.paragraphs[0]; p2.alignment = PP_ALIGN.CENTER
r2 = p2.add_run(); r2.text = "Key Functions"
r2.font.size = Pt(15); r2.font.bold = True
r2.font.color.rgb = GOLD; r2.font.name = "Calibri"
funcs = [
"🔹 Intracellular digestion",
"🔹 Cellular homeostasis",
"🔹 Immune defence (MHC-II)",
"🔹 Autophagy regulation",
"🔹 Plasma membrane repair",
"🔹 mTORC1 signalling hub",
"🔹 Cholesterol homeostasis",
"🔹 Bone resorption (osteoclasts)",
]
for f in funcs:
p3 = tf2.add_paragraph()
p3.alignment = PP_ALIGN.LEFT
p3.space_before = Pt(5)
r3 = p3.add_run(); r3.text = f
r3.font.size = Pt(12); r3.font.color.rgb = WHITE
r3.font.name = "Calibri"
# ════════════════════════════════════════════════════════════════════════════
# SLIDE 3 – Structure of Lysosome
# ════════════════════════════════════════════════════════════════════════════
def slide3_structure(prs):
sl = blank(prs)
fill_bg(sl, LIGHT_GREY)
header_bar(sl, "Structure of the Lysosome", "Membrane Architecture & Luminal Components")
bottom_bar(sl)
# Left column – structural features
add_rect(sl, Inches(0.3), Inches(1.5), Inches(6.0), Inches(5.4), WHITE)
tb = sl.shapes.add_textbox(Inches(0.45), Inches(1.6), Inches(5.7), Inches(5.2))
tf = tb.text_frame; tf.word_wrap = True; tf.margin_left = 0; tf.margin_top = 0
p = tf.paragraphs[0]; p.alignment = PP_ALIGN.LEFT
r = p.add_run(); r.text = "Structural Components"
r.font.size = Pt(16); r.font.bold = True
r.font.color.rgb = DARK_BLUE; r.font.name = "Calibri"
struct_items = [
("Lysosomal Membrane (7–10 nm):",
"Phospholipid bilayer; enriched in sphingomyelin & cholesterol for acid resistance."),
("LAMP-1 / LAMP-2 Proteins:",
"Lysosome-associated membrane proteins; protect membrane from self-digestion."),
("v-ATPase (Vacuolar H⁺ pump):",
"Pumps H⁺ ions into lumen to maintain acidic pH (4.5–5.0)."),
("Hydrolytic Enzymes (>60 types):",
"Proteases, lipases, nucleases, glycosidases, phosphatases – all require low pH."),
("Mannose-6-Phosphate (M6P) receptor:",
"Tags and traffics enzymes from Golgi → lysosomes via endosomes."),
("NPC1 & NPC2 Proteins:",
"Niemann-Pick C proteins; mediate cholesterol export from the lysosome."),
]
for title, desc in struct_items:
add_para(tf, title, 12.5, bold=True, color=MID_BLUE, bullet_char="◉", space_before=7)
add_para(tf, desc, 11.5, bold=False, color=DARK_GREY, space_before=1)
# Right column – types of lysosomes
add_rect(sl, Inches(6.6), Inches(1.5), Inches(6.4), Inches(5.4), DARK_BLUE)
tb2 = sl.shapes.add_textbox(Inches(6.75), Inches(1.6), Inches(6.1), Inches(5.2))
tf2 = tb2.text_frame; tf2.word_wrap = True; tf2.margin_left = 0; tf2.margin_top = 0
p2 = tf2.paragraphs[0]; p2.alignment = PP_ALIGN.CENTER
r2 = p2.add_run(); r2.text = "Types of Lysosomes"
r2.font.size = Pt(15); r2.font.bold = True
r2.font.color.rgb = GOLD; r2.font.name = "Calibri"
types = [
("Primary Lysosomes",
"Newly formed; contain inactive enzymes; bud from trans-Golgi network."),
("Secondary Lysosomes",
"Formed after fusion with endosomes or autophagosomes; active digestion."),
("Autolysosomes",
"Fused with autophagosomes; degrade damaged organelles (mitophagy, etc.)."),
("Residual Bodies",
"Undigested material remains; common in post-mitotic cells (neurons)."),
]
for t, d in types:
add_para(tf2, t, 13, bold=True, color=GOLD, bullet_char="★", space_before=10)
add_para(tf2, d, 11.5, bold=False, color=WHITE, space_before=2)
# ════════════════════════════════════════════════════════════════════════════
# SLIDE 4 – Lysosomes in Biotechnology
# ════════════════════════════════════════════════════════════════════════════
def slide4_biotech(prs):
sl = blank(prs)
fill_bg(sl, LIGHT_GREY)
header_bar(sl, "Lysosomes in Biotechnology",
"Exploiting Lysosomal Pathways for Biotechnological Applications")
bottom_bar(sl)
boxes = [
(Inches(0.3), Inches(1.55), "Biopharmaceutical Production",
MID_BLUE,
"• Lysosomal enzymes used as biotherapeutics (e.g. alglucosidase alfa for Pompe)\n"
"• Recombinant protein post-translational processing in ER/Golgi/lysosome axis\n"
"• CHO cell lysosomal pathways optimised to increase protein yield"),
(Inches(4.6), Inches(1.55), "Targeted Protein Degradation (TPD)",
TEAL,
"• LYTACs (Lysosome-Targeting Chimeras) recruit extracellular proteins for lysosomal degradation\n"
"• AUTACs use lysosomal/autophagy pathways to eliminate intracellular proteins\n"
"• Platform extends beyond PROTACs to membrane & secreted proteins"),
(Inches(8.9), Inches(1.55), "Nanoparticle Engineering",
DARK_BLUE,
"• Nano-carriers engineered to escape endo-lysosomal compartments (proton sponge effect)\n"
"• Mannose-6-phosphate tagged liposomes for lysosome-specific targeting\n"
"• pH-sensitive polymers release cargo only in acidic lysosomal environment"),
(Inches(0.3), Inches(4.35), "Gene Therapy",
DARK_BLUE,
"• AAV vectors exploit lysosomal recycling after receptor binding\n"
"• Endosomal escape engineering critical for mRNA/siRNA delivery\n"
"• CRISPR delivery systems use lysosome-evading lipid nanoparticles"),
(Inches(4.6), Inches(4.35), "Biosensor / Diagnostics",
TEAL,
"• Lysosomal pH sensors (fluorescent probes) detect early-stage disease\n"
"• Cathepsin activity-based probes for cancer imaging\n"
"• Exosome isolation leverages lysosomal multivesicular body (MVB) pathway"),
(Inches(8.9), Inches(4.35), "Industrial Enzymology",
MID_BLUE,
"• Lysosomal cathepsins used in food processing (meat tenderisation)\n"
"• Acid hydrolases applied in biomass breakdown\n"
"• Scale production using yeast over-expression systems"),
]
for x, y, title, color, text in boxes:
add_rect(sl, x, y, Inches(4.0), Inches(2.65), color)
tb = sl.shapes.add_textbox(x + Inches(0.12), y + Inches(0.1),
Inches(3.76), Inches(2.45))
tf = tb.text_frame; tf.word_wrap = True
tf.margin_left = 0; tf.margin_top = 0
p = tf.paragraphs[0]
r = p.add_run(); r.text = title
r.font.size = Pt(13); r.font.bold = True
r.font.color.rgb = WHITE if color != LIGHT_GREY else DARK_GREY
r.font.name = "Calibri"
for line in text.split("\n"):
line = line.strip()
if not line: continue
pp = tf.add_paragraph()
pp.space_before = Pt(3)
rr = pp.add_run(); rr.text = line
rr.font.size = Pt(10.5)
rr.font.color.rgb = WHITE
rr.font.name = "Calibri"
# ════════════════════════════════════════════════════════════════════════════
# SLIDE 5 – Drug Delivery via Lysosomes
# ════════════════════════════════════════════════════════════════════════════
def slide5_drug(prs):
sl = blank(prs)
fill_bg(sl, LIGHT_GREY)
header_bar(sl, "Drug Delivery via Lysosomes",
"Strategies, Mechanisms & Clinical Examples")
bottom_bar(sl)
# Left panel
add_rect(sl, Inches(0.3), Inches(1.5), Inches(7.0), Inches(5.5), WHITE)
tb = sl.shapes.add_textbox(Inches(0.45), Inches(1.6), Inches(6.7), Inches(5.3))
tf = tb.text_frame; tf.word_wrap = True; tf.margin_left = 0; tf.margin_top = 0
p = tf.paragraphs[0]
r = p.add_run(); r.text = "Lysosome-Targeted Drug Delivery Strategies"
r.font.size = Pt(15); r.font.bold = True; r.font.color.rgb = DARK_BLUE; r.font.name = "Calibri"
strats = [
("1. pH-Sensitive Liposomes",
"Destabilise at lysosomal pH (4.5–5.0) → burst-release of encapsulated drugs.\n"
"Example: Doxorubicin liposomes (Doxil®) in breast & ovarian cancer therapy."),
("2. Mannose-6-Phosphate (M6P) Tagged Nanocarriers",
"M6P receptor on cells recognises tagged carriers → endocytosis → lysosomal delivery.\n"
"Example: M6P-modified enzyme vehicles for Gaucher's disease."),
("3. Antibody-Drug Conjugates (ADCs)",
"Antibody binds cell-surface antigen → internalised → linker cleaved by lysosomal cathepsins.\n"
"Example: Brentuximab vedotin (Adcetris®) – cleavable Val-Cit linker."),
("4. Lysosome-Targeting Chimeras (LYTACs)",
"Bifunctional molecules route extracellular proteins to lysosomal degradation.\n"
"Example: Anti-EGFR LYTAC degrades EGFR in lung cancer cell lines (Banik et al., 2020)."),
("5. Acid-Degradable Polymeric Nanoparticles",
"Acetal/ketal linkages hydrolyse in acidic lysosomes → intracellular cargo release.\n"
"Example: siRNA delivery for gene silencing in hepatocellular carcinoma."),
]
for title, desc in strats:
add_para(tf, title, 12.5, bold=True, color=MID_BLUE, bullet_char="▶", space_before=7)
add_para(tf, desc, 11, bold=False, color=DARK_GREY, space_before=2)
# Right panel – examples table
add_rect(sl, Inches(7.6), Inches(1.5), Inches(5.4), Inches(5.5), DARK_BLUE)
tb2 = sl.shapes.add_textbox(Inches(7.75), Inches(1.6), Inches(5.1), Inches(5.3))
tf2 = tb2.text_frame; tf2.word_wrap = True; tf2.margin_left = 0; tf2.margin_top = 0
p2 = tf2.paragraphs[0]; p2.alignment = PP_ALIGN.CENTER
r2 = p2.add_run(); r2.text = "Clinical Drug Examples"
r2.font.size = Pt(14); r2.font.bold = True; r2.font.color.rgb = GOLD; r2.font.name = "Calibri"
examples = [
("Doxil® (Doxorubicin)", "pH-sensitive liposome; breast/ovarian cancer"),
("Aldurazyme® (laronidase)", "ERT via M6P-receptor; Hurler syndrome"),
("Adcetris® (Brentuximab)", "ADC; cathepsin-cleavable linker; lymphoma"),
("Cerezyme® (imiglucerase)", "ERT; macrophage targeting; Gaucher disease"),
("Mylotarg® (gemtuzumab)", "ADC; lysosomal hydrolysis; AML"),
("siRNA-LNPs (Onpattro®)", "Endosomal escape-optimised; hATTR amyloidosis"),
("Nexviazyme® (avalglucosidase)", "Next-gen ERT; Pompe disease; 2021 FDA approved"),
]
for drug, desc in examples:
add_para(tf2, drug, 12, bold=True, color=GOLD, bullet_char="💊", space_before=9)
add_para(tf2, desc, 10.5, bold=False, color=WHITE, space_before=1)
# ════════════════════════════════════════════════════════════════════════════
# SLIDE 6 – LYTAC / GLUTAC Mechanism
# ════════════════════════════════════════════════════════════════════════════
def slide6_glutac(prs):
sl = blank(prs)
fill_bg(sl, LIGHT_GREY)
header_bar(sl, "LYTAC & GLUTAC: Lysosome-Targeting Chimeras",
"A New Paradigm in Targeted Protein Degradation")
bottom_bar(sl)
# Left: LYTAC mechanism
add_rect(sl, Inches(0.3), Inches(1.5), Inches(6.2), Inches(5.5), WHITE)
tb = sl.shapes.add_textbox(Inches(0.45), Inches(1.6), Inches(5.9), Inches(5.3))
tf = tb.text_frame; tf.word_wrap = True; tf.margin_left = 0; tf.margin_top = 0
p = tf.paragraphs[0]
r = p.add_run(); r.text = "LYTAC Mechanism of Action"
r.font.size = Pt(15); r.font.bold = True; r.font.color.rgb = DARK_BLUE; r.font.name = "Calibri"
lytac_steps = [
("Step 1 – Construct design:",
"Bifunctional molecule: one end binds target protein; other end binds lysosome-internalisation receptor (ASGPR or CI-M6PR)."),
("Step 2 – Target engagement:",
"LYTAC bridges the target protein (membrane-bound or extracellular) to the internalisation receptor."),
("Step 3 – Endocytosis:",
"Receptor-mediated endocytosis internalises the ternary complex into early endosomes."),
("Step 4 – Lysosomal trafficking:",
"Endosome matures → late endosome → lysosome. Acidic pH dissociates receptor for recycling."),
("Step 5 – Proteolytic degradation:",
"Lysosomal cathepsins (B, D, L) degrade the target protein completely."),
("GLUTAC (GluNAc-LYTAC):",
"Uses N-acetylgalactosamine (GalNAc) ligands targeting ASGPR on hepatocytes for liver-targeted protein degradation. More cell-type specific than M6P-based LYTACs."),
]
for title, desc in lytac_steps:
add_para(tf, title, 12, bold=True, color=MID_BLUE, bullet_char="▸", space_before=6)
add_para(tf, desc, 11, bold=False, color=DARK_GREY, space_before=1)
# Right: Comparison & examples
add_rect(sl, Inches(6.8), Inches(1.5), Inches(6.2), Inches(5.5), DARK_BLUE)
tb2 = sl.shapes.add_textbox(Inches(6.95), Inches(1.6), Inches(5.9), Inches(5.3))
tf2 = tb2.text_frame; tf2.word_wrap = True; tf2.margin_left = 0; tf2.margin_top = 0
p2 = tf2.paragraphs[0]; p2.alignment = PP_ALIGN.CENTER
r2 = p2.add_run(); r2.text = "LYTAC vs GLUTAC Comparison"
r2.font.size = Pt(14); r2.font.bold = True; r2.font.color.rgb = GOLD; r2.font.name = "Calibri"
rows = [
("Feature", "LYTAC", "GLUTAC"),
("Receptor", "CI-M6PR", "ASGPR"),
("Tissue target", "Broad", "Liver-specific"),
("Ligand", "M6P glycopeptide", "GalNAc / GluNAc"),
("Target class", "Membrane + ECM proteins", "Serum/secreted proteins"),
("Example target", "EGFR, PD-L1, CD71", "ApoE4, PCSK9"),
("Key paper", "Banik et al., Science 2020", "Ahn et al., Nat Chem Biol 2021"),
]
# header row
hrow = rows[0]
for j, cell in enumerate(hrow):
p3 = tf2.paragraphs[0] if j == 0 and False else tf2.add_paragraph()
p3.alignment = PP_ALIGN.CENTER; p3.space_before = Pt(8)
r3 = p3.add_run(); r3.text = cell
r3.font.size = Pt(11.5); r3.font.bold = True
r3.font.color.rgb = TEAL; r3.font.name = "Calibri"
for row in rows[1:]:
combined = f"{row[0]}: {row[1]} | {row[2]}"
add_para(tf2, combined, 11, bold=False, color=WHITE, bullet_char="•", space_before=5)
add_para(tf2, "Recent: GPC3-mediated GLTAC for liver cancer (Fang et al., Acta Pharm Sin B, 2025)",
10, bold=True, color=GOLD, space_before=12)
# ════════════════════════════════════════════════════════════════════════════
# SLIDE 7 – Enzyme Replacement Therapy (ERT) & Limitations
# ════════════════════════════════════════════════════════════════════════════
def slide7_ert(prs):
sl = blank(prs)
fill_bg(sl, LIGHT_GREY)
header_bar(sl, "Enzyme Replacement Therapy (ERT)",
"Mechanism, Approved Therapies & Key Limitations")
bottom_bar(sl)
# Left: ERT mechanism
add_rect(sl, Inches(0.3), Inches(1.5), Inches(6.3), Inches(5.5), WHITE)
tb = sl.shapes.add_textbox(Inches(0.45), Inches(1.6), Inches(6.0), Inches(5.3))
tf = tb.text_frame; tf.word_wrap = True; tf.margin_left = 0; tf.margin_top = 0
p = tf.paragraphs[0]
r = p.add_run(); r.text = "ERT Mechanism"
r.font.size = Pt(15); r.font.bold = True; r.font.color.rgb = DARK_BLUE; r.font.name = "Calibri"
ert_pts = [
("Principle:",
"IV infusion of recombinant enzyme to replace deficient/dysfunctional lysosomal enzyme in LSDs."),
("Uptake pathway:",
"Recombinant enzymes tagged with Mannose-6-Phosphate (M6P) → bind CI-M6PR on cell surface → internalisation → delivery to lysosome."),
("Therapeutic effect:",
"Restores enzyme activity → clearance of accumulated substrate (glycogen, glucocerebrosides, GAGs, etc.)."),
("FDA-Approved ERTs (Selected):",
"Alglucosidase alfa (Myozyme®) – Pompe\nImiglucerase (Cerezyme®) – Gaucher type 1\nLaronidase (Aldurazyme®) – MPS I (Hurler)\nIdursulfase (Elaprase®) – MPS II (Hunter)\nAvalglucosidase alfa (Nexviazyme®) – late-onset Pompe (2021)"),
]
for title, desc in ert_pts:
add_para(tf, title, 12.5, bold=True, color=MID_BLUE, bullet_char="●", space_before=8)
add_para(tf, desc, 11, bold=False, color=DARK_GREY, space_before=1)
# Right: Limitations
add_rect(sl, Inches(6.85), Inches(1.5), Inches(6.15), Inches(5.5),
RGBColor(0x7B, 0x1F, 0x1F))
tb2 = sl.shapes.add_textbox(Inches(7.0), Inches(1.6), Inches(5.85), Inches(5.3))
tf2 = tb2.text_frame; tf2.word_wrap = True; tf2.margin_left = 0; tf2.margin_top = 0
p2 = tf2.paragraphs[0]; p2.alignment = PP_ALIGN.CENTER
r2 = p2.add_run(); r2.text = "Limitations of ERT"
r2.font.size = Pt(15); r2.font.bold = True; r2.font.color.rgb = GOLD; r2.font.name = "Calibri"
lims = [
("Cannot cross Blood–Brain Barrier (BBB):",
"Neurological LSDs (e.g. Krabbe, Niemann-Pick A) remain largely untreated by ERT."),
("Immunogenicity:",
"Anti-drug antibodies (ADAs) reduce efficacy over time; anaphylaxis risk."),
("Short half-life & biodistribution:",
"Enzymes degrade rapidly; limited penetration to avascular tissues (cartilage, bone)."),
("High Cost:",
"ERT among world's most expensive therapies ($200K–$700K/year per patient)."),
("Lifelong Treatment:",
"No curative effect; substrate re-accumulates on stopping therapy."),
("Cell-specific targeting gaps:",
"M6P-CI receptor downregulated in some cell types; reduced uptake in non-target tissues."),
]
for title, desc in lims:
add_para(tf2, title, 12, bold=True, color=GOLD, bullet_char="⚠", space_before=7)
add_para(tf2, desc, 10.5, bold=False, color=WHITE, space_before=1)
# ════════════════════════════════════════════════════════════════════════════
# SLIDE 8 – Applications of Lysosomal Engineering
# ════════════════════════════════════════════════════════════════════════════
def slide8_apps(prs):
sl = blank(prs)
fill_bg(sl, LIGHT_GREY)
header_bar(sl, "Applications of Lysosomal Engineering",
"From Rare Diseases to Cancer, Neurodegeneration & Beyond")
bottom_bar(sl)
apps = [
(Inches(0.3), Inches(1.55), "Lysosomal Storage Diseases", DARK_BLUE,
"Gaucher, Fabry, Pompe, MPS – ERT, substrate reduction therapy & gene therapy (AAV)"),
(Inches(4.65), Inches(1.55), "Oncology", MID_BLUE,
"LYTACs degrade oncoproteins (EGFR, PD-L1, HER2)\nChloroquine: lysosomal alkalisation to block autophagy in cancer\nADCs: cathepsin-activated chemotherapy release"),
(Inches(9.0), Inches(1.55), "Neurodegenerative Diseases", TEAL,
"Parkinson's – LRRK2/GBA lysosomal axis\nAlzheimer's – tau/Aβ clearance via autophagy-lysosome\nExtracellular vesicle delivery across BBB for LSDs"),
(Inches(0.3), Inches(4.2), "Gene & Cell Therapy", TEAL,
"AAV-mediated enzyme gene delivery (liver depot → systemic enzyme secretion)\nHSCT (haematopoietic stem cell transplant) reconstitutes lysosomal enzyme activity\nBase/prime editing to correct LSD mutations"),
(Inches(4.65), Inches(4.2), "Autophagy Modulation", DARK_BLUE,
"mTORC1 inhibitors (rapamycin) enhance autophagy\nAUTAC / ATTEC technology for selective organelle clearance\nTherapeutic mitophagy in heart failure & ischaemia"),
(Inches(9.0), Inches(4.2), "Emerging Platforms", MID_BLUE,
"Artificial lysosomes / synthetic organelles\nLysosomal transplantation (Alhowyan & Harisa, Biomolecules 2025)\nProbiotic EV-based ERT for BBB-crossing enzyme delivery"),
]
for x, y, title, color, text in apps:
add_rect(sl, x, y, Inches(4.05), Inches(2.45), color)
tb = sl.shapes.add_textbox(x + Inches(0.12), y + Inches(0.1),
Inches(3.82), Inches(2.28))
tf = tb.text_frame; tf.word_wrap = True; tf.margin_left = 0; tf.margin_top = 0
p = tf.paragraphs[0]
r = p.add_run(); r.text = title
r.font.size = Pt(13); r.font.bold = True; r.font.color.rgb = WHITE; r.font.name = "Calibri"
for line in text.split("\n"):
line = line.strip()
if not line: continue
pp = tf.add_paragraph(); pp.space_before = Pt(4)
rr = pp.add_run(); rr.text = "• " + line
rr.font.size = Pt(10.5); rr.font.color.rgb = WHITE; rr.font.name = "Calibri"
# ════════════════════════════════════════════════════════════════════════════
# SLIDE 9 – Recent Research & Conclusion
# ════════════════════════════════════════════════════════════════════════════
def slide9_research_conclusion(prs):
sl = blank(prs)
fill_bg(sl, LIGHT_GREY)
header_bar(sl, "Recent Research & Conclusion",
"Key 2024–2025 Studies and Summary")
bottom_bar(sl)
# Left: Recent research papers
add_rect(sl, Inches(0.3), Inches(1.5), Inches(7.2), Inches(5.5), WHITE)
tb = sl.shapes.add_textbox(Inches(0.45), Inches(1.6), Inches(6.95), Inches(5.3))
tf = tb.text_frame; tf.word_wrap = True; tf.margin_left = 0; tf.margin_top = 0
p = tf.paragraphs[0]
r = p.add_run(); r.text = "Recent Research Highlights (2024–2025)"
r.font.size = Pt(14.5); r.font.bold = True; r.font.color.rgb = DARK_BLUE; r.font.name = "Calibri"
papers = [
("Alhowyan & Harisa (2025)", "Biomolecules",
"Comprehensive review: molecular therapies → lysosomal transplantation & LDT. "
"Covers ERT, gene therapy, artificial lysosomes. (PMID 40149863)"),
("Raja et al. (2025)", "Arch Microbiol",
"Probiotic-derived extracellular vesicles (EVs) as nanocarriers for ERT; "
"can cross BBB – promising for neurological LSDs. (PMID 40208336)"),
("Fang et al. (2025)", "Acta Pharm Sin B",
"GPC3-mediated GLTACs for targeted degradation of membrane proteins in "
"hepatocellular carcinoma. Novel cell-specific lysosomal degrader."),
("Lerussi et al. (2025)", "Life (Basel)",
"Extracellular vesicles as tools for crossing the BBB to treat LSDs – "
"systematic analysis of EV engineering strategies. (PMID 39860010)"),
("Liu et al. (2025)", "Int J Nanomedicine",
"Nanoparticle-based gene & enzyme replacement therapies for CNS disorders; "
"reviews lysosomal enzyme delivery across BBB. (PMID 39925682)"),
("Xiao et al. (2025)", "Nat Commun",
"Covalent peptide-based lysosome-targeting platform for cancer immunotherapy. "
"Novel covalent LYTAC approach."),
]
for authors, journal, desc in papers:
add_para(tf, f"{authors} – {journal}", 12, bold=True, color=MID_BLUE,
bullet_char="📄", space_before=7)
add_para(tf, desc, 10.5, bold=False, color=DARK_GREY, space_before=1)
# Right: Conclusion
add_rect(sl, Inches(7.8), Inches(1.5), Inches(5.2), Inches(5.5), DARK_BLUE)
tb2 = sl.shapes.add_textbox(Inches(7.95), Inches(1.6), Inches(4.9), Inches(5.3))
tf2 = tb2.text_frame; tf2.word_wrap = True; tf2.margin_left = 0; tf2.margin_top = 0
p2 = tf2.paragraphs[0]; p2.alignment = PP_ALIGN.CENTER
r2 = p2.add_run(); r2.text = "Conclusion"
r2.font.size = Pt(16); r2.font.bold = True; r2.font.color.rgb = GOLD; r2.font.name = "Calibri"
conclusions = [
"Lysosomes are far more than 'garbage disposals' – they are dynamic signalling and degradation hubs.",
"Lysosomal engineering has produced FDA-approved therapies for rare diseases and is expanding into oncology and neurodegeneration.",
"LYTACs/GLUTACs represent a breakthrough in targeted protein degradation, extending beyond the proteasome.",
"ERT, despite limitations (BBB, immunogenicity, cost), remains the backbone of LSD treatment.",
"Next-generation platforms – EVs, artificial lysosomes, gene editing, and nanocarriers – aim to overcome these limitations.",
"The lysosome is a central therapeutic node of the 21st century.",
]
for c in conclusions:
add_para(tf2, c, 11.5, bold=False, color=WHITE, bullet_char="✔", space_before=9)
# ════════════════════════════════════════════════════════════════════════════
# SLIDE 10 – References & Thank You
# ════════════════════════════════════════════════════════════════════════════
def slide10_refs(prs):
sl = blank(prs)
fill_bg(sl, DARK_BLUE)
add_rect(sl, 0, 0, W, Inches(0.08), GOLD)
# References column
add_rect(sl, Inches(0.3), Inches(0.65), Inches(8.4), Inches(6.5), WHITE)
tb = sl.shapes.add_textbox(Inches(0.45), Inches(0.75), Inches(8.1), Inches(6.3))
tf = tb.text_frame; tf.word_wrap = True; tf.margin_left = 0; tf.margin_top = 0
p = tf.paragraphs[0]
r = p.add_run(); r.text = "References"
r.font.size = Pt(16); r.font.bold = True; r.font.color.rgb = DARK_BLUE; r.font.name = "Calibri"
refs = [
"1. de Duve C. (1955). Lysosomes, a new group of cytoplasmic particles. Biochem J.",
"2. Banik SM et al. (2020). Lysosome-targeting chimaeras for degradation of extracellular proteins. Science, 367(6481), 1033-1036.",
"3. Ahn G et al. (2021). LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat Chem Biol, 17, 937-946.",
"4. Alhowyan AA & Harisa GI. (2025). From Molecular Therapies to Lysosomal Transplantation. Biomolecules, 15(3), 327. PMID 40149863.",
"5. Raja M et al. (2025). Bacterial-derived EVs for targeted ERT. Arch Microbiol. PMID 40208336.",
"6. Lerussi G et al. (2025). Extracellular Vesicles for crossing BBB to treat LSDs. Life (Basel). PMID 39860010.",
"7. Liu S et al. (2025). Nanoparticle-based gene & ERT for CNS disorders. Int J Nanomedicine. PMID 39925682.",
"8. Fang Y et al. (2025). GPC3-mediated GLTACs for targeted degradation. Acta Pharm Sin B, 15(4), 2156-2169.",
"9. Brady RO et al. (1974). Gaucher's disease and enzyme therapy. NEJM.",
"10. Ballabio A & Bonifacino JS. (2020). Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat Rev Mol Cell Biol, 21, 101-118.",
"11. Junqueira's Basic Histology, 17e – Lysosomes chapter.",
"12. Guyton & Hall Textbook of Medical Physiology – Cell structure.",
"13. Zhou X et al. (2025). Challenges and opportunities for lysosome-targeting chimeras. Cell Rep Phys Sci.",
]
for ref in refs:
add_para(tf, ref, 10, bold=False, color=DARK_GREY, space_before=4)
# Thank You panel
add_rect(sl, Inches(9.0), Inches(0.65), Inches(4.0), Inches(6.5), TEAL)
tb2 = sl.shapes.add_textbox(Inches(9.15), Inches(1.8), Inches(3.7), Inches(4.0))
tf2 = tb2.text_frame; tf2.word_wrap = True; tf2.margin_left = 0; tf2.margin_top = 0
p2 = tf2.paragraphs[0]; p2.alignment = PP_ALIGN.CENTER
r2 = p2.add_run(); r2.text = "Thank You!"
r2.font.size = Pt(32); r2.font.bold = True; r2.font.color.rgb = WHITE; r2.font.name = "Calibri"
add_para(tf2, "", 12, space_before=8)
add_para(tf2, "Questions & Discussion", 16, bold=True, color=GOLD,
align=PP_ALIGN.CENTER, space_before=8)
add_para(tf2, "", 12, space_before=8)
add_para(tf2, "\"The lysosome is not the cell's graveyard —\nit is the cell's rebirth chamber.\"",
12, bold=False, color=WHITE, align=PP_ALIGN.CENTER, italic=True, space_before=10)
add_rect(sl, Inches(9.0), Inches(6.85), Inches(4.0), Inches(0.3), GOLD)
# ════════════════════════════════════════════════════════════════════════════
# MAIN
# ════════════════════════════════════════════════════════════════════════════
def main():
prs = new_prs()
slide1_title(prs)
slide2_intro(prs)
slide3_structure(prs)
slide4_biotech(prs)
slide5_drug(prs)
slide6_glutac(prs)
slide7_ert(prs)
slide8_apps(prs)
slide9_research_conclusion(prs)
slide10_refs(prs)
out = "/tmp/workspace/lysosomal-engineering/Lysosomal_Engineering.pptx"
buf = BytesIO()
prs.save(buf)
with open(out, "wb") as f:
f.write(buf.getvalue())
print(f"Saved: {out} ({len(buf.getvalue())//1024} KB)")
if __name__ == "__main__":
main()
cd /tmp/workspace/lysosomal-engineering && python build_pptx.py 2>&1
~/lysosomal-engineering/build_pptx.py
Successfully replaced 1 instance(s) of the string in '/tmp/workspace/lysosomal-engineering/build_pptx.py'
cd /tmp/workspace/lysosomal-engineering && python build_pptx.py 2>&1
Lysosomal Engineering
Presentation · PPTX
Presentation Overview - 10 Slides
| # | Slide Title | Content Highlights |
|---|---|---|
| 1 | Title Slide | "Lysosomal Engineering" - professional dark-blue theme with gold accents |
| 2 | Introduction to Lysosomes | Discovery (de Duve, 1955), definition, pH 4.5-5.0, >60 hydrolases, 8 key functions, LSDs |
| 3 | Structure of the Lysosome | Membrane (LAMP-1/2, v-ATPase, M6P receptor, NPC1/2); 4 types of lysosomes |
| 4 | Lysosomes in Biotechnology | 6 application boxes: biopharma, TPD, nanoparticles, gene therapy, diagnostics, industrial enzymology |
| 5 | Drug Delivery with Examples | 5 strategies (pH liposomes, M6P nanocarriers, ADCs, LYTACs, acid-degradable NPs) + 7 clinical drug examples (Doxil, Cerezyme, Adcetris, etc.) |
| 6 | LYTAC & GLUTAC Mechanism | 5-step LYTAC mechanism, GLUTAC (GalNAc/ASGPR), side-by-side comparison table, 2025 research highlight |
| 7 | ERT & Limitations | ERT mechanism (M6P pathway), 5 FDA-approved therapies, 6 limitations (BBB, immunogenicity, cost, etc.) |
| 8 | Applications of Lysosomal Engineering | 6 application areas: LSDs, oncology, neurodegeneration, gene/cell therapy, autophagy modulation, emerging platforms |
| 9 | Recent Research & Conclusion | 6 papers from 2024-2025 (with PMIDs); conclusion bullets summarising the field |
| 10 | References & Thank You | 13 numbered references (PubMed + textbooks); "Thank You" panel with discussion prompt |
With including some pictures about that
lysosome structure diagram membrane
This pathophysiology diagram illustrates the sequential stages of macroautophagy, a critical cellular degradation pathway. The process initiates with the 'Isolation membrane' (pre-autophagosomal structure), mediated by the ULK1 complex involving WIPI and PI3P. This evolves into a crescent-shaped 'Phagophore' which sequester cytoplasmic components. The diagram highlights the elongation and maturation phase, showing the recruitment of the ATG12-ATG5-ATG16L1 complex and the lipidation of LC3 (converting LC3 I to LC3 II) to facilitate membrane closure. This results in the formation of a double-membraned 'Autophagosome' containing internal cargo and membrane-bound LC3BII. In the final phase, the autophagosome fuses with a 'Lysosome' containing hydrolytic enzymes to form an 'Autopolysosome' (autolysosome), where the sequestered material is degraded. Key molecular markers like LC3BII are depicted throughout the maturation steps. This illustration is relevant for teaching basic cell biology, molecular signaling, and pathophysiology in contexts like Diabetic Kidney Disease (DKD), where autophagic flux regulation is a therapeutic target.
A medical educational diagram illustrating the structure and biogenesis of extracellular vesicles (exosomes and microvesicles). The top panel shows a high-magnification cross-section of an individual vesicle, highlighting its phospholipid bilayer membrane containing surface antigens, adhesion molecules, tetraspanins, and lipid rafts. The internal lumen is shown carrying cargo such as nucleic acids, proteins, and lipids. The bottom panel depicts the cellular production pathway. It begins with the internalization of the plasma membrane to form an early endosome (EE), which matures into a multivesicular endosome (MVE) or multivesicular body (MVB) containing intraluminal vesicles (ILV). This maturation step is annotated with the regulatory protein Rab27A. The diagram shows two possible fates for the MVE: fusion with the plasma membrane to release exosomes (30–100 nm) into the extracellular space via exocytosis, or fusion with a lysosome for cargo degradation. The illustration uses standard biomedical iconography to teach cellular signaling and transport mechanisms.
This medical schematic diagram illustrates the molecular and morphological stages of macroautophagy. Section (a) depicts the progression from pre-autophagosomal structures to the autolysosome. It begins with the formation of a crescent-shaped phagophore (pre-autophagosomal structure) associated with the Atg5-Atg12-Atg16L1 complex (purple) and lipidated LC3-II (green). The phagophore elongates to engulf autophagic cargo, including mitochondria and other cellular debris, closing to form a double-membrane autophagosome. After closure, the Atg complex dissociates, and the autophagosome fuses with a lysosome (red) to form an autolysosome, leading to the enzymatic degradation of the internal cargo. Section (b) outlines the biochemical pathway for LC3 lipidation. The protease Atg4 cleaves LC3 to expose a glycine residue, forming LC3-I. Subsequently, Atg7 and Atg3 facilitate the conjugation of LC3-I to phosphatidylethanolamine (PE), producing the lipidated form LC3-II, which then anchors to the autophagosomal membrane. This diagram serves as an educational resource for cell biology and molecular pathology, specifically regarding intracellular degradation pathways.
lysosome drug delivery nanoparticle
A comparative medical schematic illustrating the cellular uptake and pharmacokinetics of conventional versus nanoparticle-based drug delivery within a cancer cell. The diagram is divided into two sections. The left side depicts 'Conventional drugs' utilizing active transport and passive transport for cellular entry, while also highlighting mechanisms of drug efflux. This delivery method is associated with clinical challenges such as off-target drug diffusion, rapid elimination, and low bioavailability. The right side depicts 'Nanoparticle drugs' entering the cell via endocytosis. The illustration shows a nanoparticle encapsulated within a lysosome, facilitating intracellular release. This method is characterized by therapeutic advantages including targeted drug delivery, prolonged systemic circulation, and high bioavailability. The diagram serves as an educational tool in pharmacology and oncology to demonstrate how nanotechnology can overcome biological barriers and improve drug efficacy while minimizing systemic toxicity.
A medical schematic diagram illustrating the structural architecture of a multifunctional nanoparticle designed for targeted drug delivery. The cross-sectional view shows an aqueous core containing orange capsule-shaped hydrophilic drugs, encapsulated by a yellow phospholipid bilayer. This lipid layer hosts green wedge-shaped hydrophobic drugs within its hydrophobic tail region. The nanoparticle's surface is functionalized with multiple bioactive ligands, as defined by the accompanying legend: gray key-shaped imaging agents for diagnostic tracking, yellow starburst-shaped specific targeting moieties for site-directed delivery, blue coiled biocompatible polymers (such as PEG) to enhance stability and circulation time, and red arrows representing cell-penetrating agents to facilitate intracellular uptake. This illustration demonstrates a nanocarrier system capable of co-delivering diverse therapeutic agents while simultaneously providing diagnostic imaging and cellular targeting capabilities, particularly relevant in pharmacological research for treating protected anatomical regions like the inner ear.
This composite educational graphic illustrates the characterization of a nanoparticle-based drug delivery system. (a) Scanning Electron Microscopy (SEM) image showing bovine serum albumin (BSA)-laden poly(lactic-co-glycolic acid) (PLGA) nanoparticles. The nanoparticles exhibit a predominantly spherical morphology with smooth surfaces; however, significant aggregation is visible, attributed to the freeze-drying process. A 200 nm scale bar is provided for size reference. (b) Attenuated Total Reflectance-Fourier Transform Infrared (ATR-FTIR) spectra comparing pure BSA (blue line), pure PLGA (black line), and BSA-laden PLGA nanoparticles (red line). The PLGA spectrum identifies characteristic monomer sequence peaks at 1381, 1424, and 1452 cm−1, alongside C=O and C-O stretching. The BSA spectrum displays protein-specific amide I (1643 cm−1) and amide II (1527 cm−1) peaks. The nanoparticle (NP) spectrum demonstrates successful encapsulation by incorporating characteristic peaks from both the polymer matrix and the protein cargo. This material is relevant for pharmacology and biomedical engineering studies focused on sustained-release ocular drug delivery.
enzyme replacement therapy lysosomal storage disease
This medical pathophysiology diagram illustrates the schematic process of Organelle Replacement Therapy (ORT) for Lysosomal Storage Diseases (LSD). The workflow is divided into three primary stages. 1) Extraction: Healthy lysosomes containing functional lysosomal enzymes are harvested from a 'Normal cell'. 2) Modification: The molecular structure of the modification agent, Stearyl-His16 (STR-His16), is detailed, showing a stearyl moiety (CH3(CH2)16CONH-) attached to the N-terminus of a 16-residue histidine chain. This hydrophobic stearyl group is inserted into the lysosomal membrane's lipid bilayer to create 'His16-Lyso'. 3) Delivery: The modified lysosomes are transported into an 'LSD cell', where they reach and merge with endogenous, dysfunctional lysosomes. The educational focus is on a novel enzyme replacement strategy that utilizes intact organelle transport rather than isolated protein delivery. The diagram uses color-coded cells (yellow for normal, grey for LSD) and detailed chemical structures to explain the pharmacological mechanism of membrane modification and cellular uptake.
This clinical photograph comparison (A and B) illustrates the physical manifestations and therapeutic response of a pediatric patient with Gaucher disease. Image A shows a child with severe abdominal distension, representing massive hepatosplenomegaly. Visible dark markings on the skin indicate the anatomical borders of the enlarged liver and spleen prior to medical intervention. Image B displays the same child following enzyme replacement therapy (ERT), demonstrating a significant reduction in abdominal girth and regression of hepatosplenomegaly to a more typical size. The comparison highlights the clinical efficacy of ERT in managing visceral symptoms of lysosomal storage disorders. Beyond the physiological changes, there is a notable improvement in the child's apparent comfort and affect, transitioning from a neutral/stressed state in A to a comfortable, smiling appearance in B. This visual is used in medical education to teach the clinical presentation of metabolic genetic diseases and the impact of systemic targeted therapies.
Transmission electron microscopy image of human cardiac tissue from a Fabry disease case shows hallmark lysosomal storage inclusions within cardiomyocytes and vascular endothelium. At high magnification, numerous lysosomes contain concentric lamellae forming zebra bodies or myelin figures, reflecting accumulation of globotriaosylceramide (Gb3) due to alpha-galactosidase A deficiency. The ultrastructural features include enlarged, electron-dense lysosomes with alternating dense and light lamellae and cytoplasmic vacuolization, consistent with sphingolipid storage. The tissue plane focuses on myocardial cells and microvascular elements; scale bar indicates ~1 μm, with magnification around 7000×, enabling subcellular visualization of organelle pathology. This image demonstrates the intracellular bottleneck of Gb3 trafficking that underlies multi-organ involvement in Fabry disease, including cardiac hypertrophy, renal failure, and cerebrovascular events. Clinically, these findings support diagnosis when correlated with enzyme assay and genetic testing, and they illustrate the impact of early enzyme replacement therapy on prognosis. Postmortem, such ultrastructural evidence aligns with progressive cardiomyopathy and vascular Gb3 deposition. The image is a valuable teaching resource for medical students, pathologists, and researchers, capturing the microscopic basis of Fabry-related cardiomyopathy and the rationale for disease-specific management and prognosis. Interpretation should be integrated with clinical history, biochemical Gb3 quantification, and genetic confirmation for comprehensive care planning.
autophagy lysosome fusion autolysosome pathway
This pathophysiology diagram illustrates the multi-step process of autophagy and its regulation by Tripartite Motif-containing (TRIM) proteins. The pathway is divided into several morphological stages: initiation, membrane nucleation, phagophore formation, autophagosome maturation, and lysosomal fusion. Key regulatory nodes include the MTOR complex (Deptor, Raptor, mLST8, PRAS40) and the ULK1 complex (ATG13, RB1CC1), which trigger membrane nucleation. TRIM proteins are shown as primary modulators at every stage: TRIM6 and TRIM28 inhibit MTOR; TRIM37 regulates TFEB; and various TRIMs (e.g., TRIM5, 16, 17, 21) influence the BECN1-PIK3C3-PIK3R4 nucleation complex. The diagram depicts the phagophore engulfing cellular cargo including Ubiquitin (Ub) and Autophagy Receptors (AR), then maturing into a double-membraned autophagosome. Specific components like MAP1LC3B2 and the ATG12-ATG5-ATG16L1 complex are shown facilitating membrane expansion. Finally, the autophagosome fuses with a lysosome (mediated by RAB7A and TRIM39) to form an autolysosome for cargo degradation. This visual serves as a comprehensive educational map of molecular signaling in cellular homeostasis.
A pathophysiology diagram illustrating the four major stages of the autophagy pathway: Initiation, Elongation and Maturation, AL Fusion, and Degradation. At the Initiation stage, the ULK1 complex (ULK1, ATG13, FIP200, ATG101) is shown being inhibited by mTOR kinase. During Elongation and Maturation, LC3 is processed into LC3 I and then LC3 II. A phagophore membrane expands into a crescent shape to engulf cellular cargo including mitochondria, ribosomes, and nucleic acids, often tagged with p62 adapters, eventually forming a double-membraned autophagosome. The AL (Autolysosome) Fusion stage depicts the docking and merging of the autophagosome with a lysosome containing acid hydrolases. In the final Degradation stage, the diagram shows the breakdown of the autolysosomal contents into basic molecular building blocks, including amino acids, fatty acids, and nucleotides. This schematic serves as a medical educational resource for cell biology and molecular signaling, detailing the morphological and biochemical progression of macroautophagy.
LYTAC lysosome targeting chimera protein degradation mechanism
A scientific infographic illustrating Targeted Protein Degradation (TPD) pathways, organized into three functional domains. The left section details the Ubiquitin-Proteasome System (UPS), showing the enzymatic cascade of E1, E2, and E3 ligases facilitating polyubiquitination (Ub) and subsequent proteasomal degradation of substrate proteins. Below this, different PROTAC (Proteolysis-Targeting Chimera) strategies are highlighted, including PhotoPROTACs for light-reversible activation, CLIPTACs for intracellular self-assembly, and Oligonucleotide-based PROTACs for targeting RNA-binding proteins (RBPs) and transcription factors (TFs). The right section illustrates non-proteasomal degradation pathways hijacked by TPDs. The Autophagy pathway demonstrates a double-membrane autophagosome engulfing cellular components and fusing with a lysosome (related to ATTEC, AUTOTAC, and AUTAC technologies). The Lysosomal pathway depicts receptor-mediated endocytosis at the plasma membrane and subsequent lysosomal degradation (related to LYTAC, CI-M6PR, and IFLD technologies). This diagram serves as an educational summary of how synthetic molecules can redirect various cellular waste management systems to degrade specific proteins of interest (POI).
This pathophysiology diagram illustrates the catalytic mechanism of Proteolysis-Targeting Chimera (PROTAC) technology for targeted protein degradation. The process begins with a PROTAC molecule, consisting of a Target Protein Ligand (TPL) and a Ubiquitin Ligase Ligand (ULL) joined by a linker. The PROTAC recruits a target protein (TP, green) and an E3 ubiquitin ligase (UL, orange) to form a ternary complex. The diagram shows the subsequent ubiquitination phase, where a ubiquitin chain (Ub) is transferred to the target protein. This leads to recognition and breakdown of the TP by the Ubiquitin Proteasome System (UPS), resulting in degraded protein fragments. The PROTAC molecule is then released intact, demonstrating its catalytic recycling capability. The infographic further summarizes clinical context, listing advantages such as targeting 'undruggable' proteins and overcoming drug resistance, alongside pharmacological limitations like poor oral bioavailability and off-target toxicity. This visual serves as an educational resource for understanding signaling pathways and novel therapeutic modalities in drug discovery.
Gaucher disease Fabry disease lysosomal storage
A pathophysiology diagram illustrating the lysosomal metabolic pathways of ceramide and their association with specific lysosomal storage diseases. The central metabolic axis details the conversion of Globotriosylceramide to Lactosylceramide via the enzyme GLA (deficient in Fabry disease), Lactosylceramide to Glucosylceramide, and Glucosylceramide to Ceramide via GCase (deficient in Gaucher disease). Parallel pathways show Galactosylceramide being converted to Ceramide by GALC (deficient in Krabbe disease) and Sphingomyelin being converted by ASMase (deficient in Niemann-Pick disease). The diagram includes a cellular illustration featuring a magnified lysosome to contextualize these processes within the organelle. Additional boxes categorize related metabolic disorders: Sphingolipidosis (Fabry, Gaucher, Krabbe, Niemann-Pick), Glycogenosis (Pompe disease/GAA deficiency), and Mucopolysaccharidoses (MPS Type I/IDUA deficiency). An arrow suggests that lysosomal disruption from glycogen or mucopolysaccharide accumulation can lead to secondary storage of products influencing the ceramide pathway. This educational visual is designed for medical genetics and biochemistry to explain enzyme-substrate relationships in sphingolipid metabolism.
Two-panel clinical photograph illustrating the dermatological manifestations of Fabry disease, a lysosomal storage disorder. The left panel shows a cluster of red-purple, non-blanching vascular skin lesions known as angiokeratomas localized around the umbilicus. These lesions appear as small, discrete macules and papules that coalesce into irregular patches. The right panel demonstrates similar vascular lesions affecting the mucosal surface of the upper lip and the vermilion border. The lesions are characteristic of the 'bathing trunk' distribution seen in affected patients, appearing as dark red to purple telangiectatic spots. The image also captures the oral cavity, where dental plaque and mild gingival inflammation are visible. These visual signs are critical diagnostic markers for alpha-galactosidase A deficiency, serving as early indicators of multisystemic glycolipid accumulation in both pediatric and adult populations.
python /tmp/skills/shared/scripts/fetch_images.py \ "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_de74aba820bf001e03e971a948f8f90f5869e7eb2bc2e5f436413ccbc39427f9.jpg" \ "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_c9082a4d11e4abbc8dd9c683477c636f3e3fb9f80e530c538e1808db75d25727.jpg" \ "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_139f8b901a1c3a0dc1b39866e674cd0133a3477765c80bcecb2100ac702d4637.jpg" \ "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_0b4ccbfe4944f8edd7de50fb486e89430156702328eea67f27ef171bc1ff86c.jpg" \ "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_fa5b9c2148a91768c051ecb7352eec32a2bdaf710809547a7e1cb667e7e1979c.jpg" \ "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_621d51550d46ac46fdffce424b19d55557574b64e2a0240eb715f74a66abcc86.jpg" \ "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_3f42cdb340944a0a7c236378bc00fa072186abcfe9248d89e2ff2ff368c6fa3d.jpg" 2>&1 | head -5
Rebuild